Showing results (71-80 of 79) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 79 results.
Cancer Management and Research|July 2, 2020
Multiple Immune-Related Adverse Events and Anti-Tumor Efficacy: Real-World Data on Various Solid TumorsKeitaro Shimozaki, Yasutaka Sukawa, Noriko Beppu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2025
Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High Advanced Gastric or Esophagogastric Junction CancerHisato Kawakami, Shigenori Kadowaki, Akitaka Makiyama, et al.
Oncology Letters|October 11, 2024
Clinical characteristics of gastrointestinal stromal tumors with hypoglycemiaAkihiko Chida, Kenta Kawasaki, Junko Kuramoto, et al.
The Oncologist|August 17, 2023
Pre-existing Interstitial Lung Abnormalities and Immune Checkpoint Inhibitor-Related Pneumonitis in Solid Tumors: A Retrospective AnalysisKohei Horiuchi, Shinnosuke Ikemura, Takashi Sato, et al.
Clinical Colorectal Cancer|September 18, 2022
WJOG13219G: The Efficacy and Safety of FOLFOXIRI or Doublet plus Anti-VEGF Therapy in Previously Untreated BRAFV600E Mutant Metastatic Colorectal Cancer: A Multi-Institutional Registry-Based Study (BRACELET Study)Keitaro Shimozaki, Kenro Hirata, Taro Sato, et al.
Eclinicalmedicine|February 9, 2026
Solvent-based or nab-paclitaxel plus ramucirumab for pretreated gastric cancer with peritoneal dissemination and prespecified biomarker analysis (P-SELECT/WJOG10617G): a randomised phase 2 trial in JapanKenro Hirata, Yasuo Hamamoto, Hirokazu Shoji, et al.
Targeted Oncology|March 1, 2024
A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer: WJOG 11018GToshihiko Matsumoto, Yoshiyuki Yamamoto, Masahito Kotaka, et al.
Scientific Reports|March 7, 2025
The efficacy and safety of FOLFOX therapy for advanced esophageal squamous cell carcinomaKazuhiro Shiraishi, Mao Okada, Shun Yamamoto, et al.
European Journal of Cancer (Oxford, England : 1990)|March 25, 2026
Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST)Yosuke Kito, Kentaro Yamazaki, Hirokazu Shoji, et al.
Pageof 8